Published in Anesthesiology on September 01, 2007
Antinociceptive effects of nociceptin/orphanin FQ administered intrathecally in monkeys. J Pain (2009) 1.14
Roles of μ-opioid receptors and nociceptin/orphanin FQ peptide receptors in buprenorphine-induced physiological responses in primates. J Pharmacol Exp Ther (2012) 1.07
Long-lasting antinociceptive spinal effects in primates of the novel nociceptin/orphanin FQ receptor agonist UFP-112. Pain (2009) 1.05
The therapeutic potential of nociceptin/orphanin FQ receptor agonists as analgesics without abuse liability. ACS Chem Neurosci (2012) 0.94
Effects of atypical kappa-opioid receptor agonists on intrathecal morphine-induced itch and analgesia in primates. J Pharmacol Exp Ther (2008) 0.94
Neuraxial opioid-induced pruritus: An update. J Anaesthesiol Clin Pharmacol (2013) 0.93
Anatomy and neurophysiology of pruritus. Semin Cutan Med Surg (2011) 0.89
Effects of mu, kappa, and delta opioid receptor agonists on the function of hypothalamic-pituitary-adrenal axis in monkeys. Psychoneuroendocrinology (2008) 0.89
Intravenous butorphanol administration reduces intrathecal morphine-induced pruritus after cesarean delivery: a randomized, double-blind, placebo-controlled study. J Anesth (2012) 0.82
Distinct functions of opioid-related peptides and gastrin-releasing peptide in regulating itch and pain in the spinal cord of primates. Sci Rep (2015) 0.78
Neuraxial opioid-induced itch and its pharmacological antagonism. Handb Exp Pharmacol (2015) 0.75
Severe pruritus and myoclonus following intrathecal morphine administration in a dog. Can Vet J (2012) 0.75
The neurobiology of itch. Nat Rev Neurosci (2006) 3.25
Intrathecal and epidural administration of opioids. Anesthesiology (1984) 2.91
Dose-response pharmacology of intrathecal morphine in human volunteers. Anesthesiology (1993) 2.01
Comparison of pharmacological activities of three distinct kappa ligands (Salvinorin A, TRK-820 and 3FLB) on kappa opioid receptors in vitro and their antipruritic and antinociceptive activities in vivo. J Pharmacol Exp Ther (2004) 1.89
Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans. Psychopharmacology (Berl) (2001) 1.68
Comparison of the sedative effects of butorphanol and midazolam. Anesthesiology (1991) 1.64
A comparison of the incidence of pruritus following epidural opioid administration in the parturient. Can J Anaesth (1989) 1.54
Intrathecal drug therapy for chronic pain: from basic science to clinical practice. Anesthesiology (1999) 1.54
How best to fight that nasty itch - from new insights into the neuroimmunological, neuroendocrine, and neurophysiological bases of pruritus to novel therapeutic approaches. Exp Dermatol (2005) 1.51
Primer of postoperative pruritus for anesthesiologists. Anesthesiology (2005) 1.47
Characterization of opioid agonist efficacy in a C6 glioma cell line expressing the mu opioid receptor. J Pharmacol Exp Ther (1996) 1.39
Kappa-opioid system in uremic pruritus: multicenter, randomized, double-blind, placebo-controlled clinical studies. J Am Soc Nephrol (2005) 1.34
The role of central mu opioid receptors in opioid-induced itch in primates. J Pharmacol Exp Ther (2004) 1.33
Kappa opioid antagonist effects of systemically administered nor-binaltorphimine in a thermal antinociception assay in rhesus monkeys. J Pharmacol Exp Ther (1993) 1.27
Antipruritic activity of the kappa-opioid receptor agonist, TRK-820. Eur J Pharmacol (2002) 1.26
Dose-response relationship of intrathecal morphine for postcesarean analgesia. Anesthesiology (1999) 1.26
An experimental itch model in monkeys: characterization of intrathecal morphine-induced scratching and antinociception. Anesthesiology (2000) 1.21
Post-caesarean section analgesia: a comparison of epidural butorphanol and morphine. Can J Anaesth (1991) 1.11
Kappa opioid antagonist effects of the novel kappa antagonist 5'-guanidinonaltrindole (GNTI) in an assay of schedule-controlled behavior in rhesus monkeys. Psychopharmacology (Berl) (2002) 1.09
Diuretic actions in man of a selective kappa opioid agonist: U-62,066E. J Pharmacol Exp Ther (1987) 1.08
A controlled trial of naloxone infusions for the pruritus of chronic cholestasis. Gastroenterology (1992) 1.08
Activation of kappa-opioid receptors inhibits pruritus evoked by subcutaneous or intrathecal administration of morphine in monkeys. J Pharmacol Exp Ther (2003) 1.05
Characterization of scratching responses in rats following centrally administered morphine or bombesin. Behav Pharmacol (2003) 1.05
Opioid efficacy in a C6 glioma cell line stably expressing the human kappa opioid receptor. J Pharmacol Exp Ther (1999) 1.04
Comparison of intravenous nalbuphine infusion versus naloxone in the prevention of epidural morphine-related side effects. Reg Anesth Pain Med (1998) 1.01
Mu and kappa1 opioid-stimulated [35S]guanylyl-5'-O-(gamma-thio)-triphosphate binding in cynomolgus monkey brain. Neuroscience (1999) 0.97
In vivo determination of mu opioid receptor turnover in rhesus monkeys after irreversible blockade with clocinnamox. J Pharmacol Exp Ther (1994) 0.97
Nalbuphine is better than naloxone for treatment of side effects after epidural morphine. Anesth Analg (1992) 0.96
Studies of micro-, kappa-, and delta-opioid receptor density and G protein activation in the cortex and thalamus of monkeys. J Pharmacol Exp Ther (2003) 0.94
Evidence-based review of the literature on intrathecal delivery of pain medication. J Pain Symptom Manage (2000) 0.94
Continuous epidural butorphanol relieves pruritus associated with epidural morphine infusions in children. Paediatr Anaesth (2000) 0.93
Human psychopharmacology of ketocyclazocine as compared with cyclazocine, morphine and placebo. J Pharmacol Exp Ther (1986) 0.93
Butorphanol: characterization of agonist and antagonist effects in rhesus monkeys. J Pharmacol Exp Ther (1995) 0.91
Epidural morphine with butorphanol for postoperative analgesia after cesarean delivery. Anesth Analg (1991) 0.90
Comparing the subjective, psychomotor and physiological effects of intravenous butorphanol and morphine in healthy volunteers. J Pharmacol Exp Ther (1994) 0.89
Influence of naloxone infusion on analgesia and respiratory depression following epidural morphine. Anesthesiology (1986) 0.89
Transnasal butorphanol for the treatment of opioid-induced pruritus unresponsive to antihistamines. J Pain Symptom Manage (1996) 0.88
kappa-Opioid receptor effects of butorphanol in rhesus monkeys. J Pharmacol Exp Ther (1999) 0.84
Effects of fentanyl on vasopressin secretion in human subjects. J Pharmacol Exp Ther (1987) 0.78
Treatment of the Pruritus of Cholestasis. Curr Treat Options Gastroenterol (2004) 0.77
A series of anesthesia-related maternal deaths in Michigan, 1985-2003. Anesthesiology (2007) 2.47
Most efficient cocaine hydrolase designed by virtual screening of transition states. J Am Chem Soc (2008) 2.33
Yawning and hypothermia in rats: effects of dopamine D3 and D2 agonists and antagonists. Psychopharmacology (Berl) (2007) 1.94
Dopamine agonist-induced yawning in rats: a dopamine D3 receptor-mediated behavior. J Pharmacol Exp Ther (2005) 1.87
A bacterial cocaine esterase protects against cocaine-induced epileptogenic activity and lethality. Ann Emerg Med (2008) 1.77
Behavioral and neurochemical consequences of long-term intravenous self-administration of MDMA and its enantiomers by rhesus monkeys. Neuropsychopharmacology (2004) 1.71
Rapid and robust protection against cocaine-induced lethality in rats by the bacterial cocaine esterase. Mol Pharmacol (2006) 1.66
Thermostable variants of cocaine esterase for long-time protection against cocaine toxicity. Mol Pharmacol (2008) 1.60
Identifying patients at high risk for venous thromboembolism requiring treatment after outpatient surgery. Ann Surg (2012) 1.55
Cocaine esterase: interactions with cocaine and immune responses in mice. J Pharmacol Exp Ther (2006) 1.55
The economics of drug abuse: a quantitative assessment of drug demand. Mol Interv (2005) 1.54
Design, preparation, and characterization of high-activity mutants of human butyrylcholinesterase specific for detoxification of cocaine. Mol Pharmacol (2010) 1.48
Nonpeptidic delta-opioid receptor agonists reduce immobility in the forced swim assay in rats. Neuropsychopharmacology (2002) 1.45
Food restriction alters N'-propyl-4,5,6,7-tetrahydrobenzothiazole-2,6-diamine dihydrochloride (pramipexole)-induced yawning, hypothermia, and locomotor activity in rats: evidence for sensitization of dopamine D2 receptor-mediated effects. J Pharmacol Exp Ther (2008) 1.31
Drug and reinforcement history as determinants of the response-maintaining effects of quinpirole in the rat. J Pharmacol Exp Ther (2007) 1.31
Delta-opioid agonists: differential efficacy and potency of SNC80, its 3-OH (SNC86) and 3-desoxy (SNC162) derivatives in Sprague-Dawley rats. J Pharmacol Exp Ther (2004) 1.25
LARGE SCALE PURIFICATION OF BUTYRYLCHOLINESTERASE FROM HUMAN PLASMA SUITABLE FOR INJECTION INTO MONKEYS; A POTENTIAL NEW THERAPEUTIC FOR PROTECTION AGAINST COCAINE AND NERVE AGENT TOXICITY. J Med Chem Biol Radiol Def (2005) 1.24
Relative analgesic potencies of levobupivacaine and ropivacaine for epidural analgesia in labor. Anesthesiology (2003) 1.19
Cocaine esterase prevents cocaine-induced toxicity and the ongoing intravenous self-administration of cocaine in rats. J Pharmacol Exp Ther (2009) 1.19
Convulsant activity of a non-peptidic delta-opioid receptor agonist is not required for its antidepressant-like effects in Sprague-Dawley rats. Psychopharmacology (Berl) (2002) 1.18
Effects of buprenorphine maintenance dose on mu-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers. Neuropsychopharmacology (2003) 1.18
Behavioral effects of a synthetic agonist selective for nociceptin/orphanin FQ peptide receptors in monkeys. Neuropsychopharmacology (2009) 1.18
Behavioral sensitization to cocaine in rats: evidence for temporal differences in dopamine D3 and D2 receptor sensitivity. Psychopharmacology (Berl) (2011) 1.18
Patterns of nicotinic receptor antagonism: nicotine discrimination studies. J Pharmacol Exp Ther (2011) 1.18
Pharmacological characterization of the effects of 3,4-methylenedioxymethamphetamine ("ecstasy") and its enantiomers on lethality, core temperature, and locomotor activity in singly housed and crowded mice. Psychopharmacology (Berl) (2003) 1.17
Comparison of receptor mechanisms and efficacy requirements for delta-agonist-induced convulsive activity and antinociception in mice. J Pharmacol Exp Ther (2002) 1.15
Antinociceptive effects of nociceptin/orphanin FQ administered intrathecally in monkeys. J Pain (2009) 1.14
Structural determinants of opioid activity in derivatives of 14-aminomorphinones: effect of substitution in the aromatic ring of cinnamoylaminomorphinones and codeinones. J Med Chem (2006) 1.13
A thermally stable form of bacterial cocaine esterase: a potential therapeutic agent for treatment of cocaine abuse. Mol Pharmacol (2010) 1.12
Characterization of the complex morphinan derivative BU72 as a high efficacy, long-lasting mu-opioid receptor agonist. Eur J Pharmacol (2004) 1.12
Kappa-opioid receptor-mediated effects of the plant-derived hallucinogen, salvinorin A, on inverted screen performance in the mouse. Behav Pharmacol (2005) 1.10
3,4-Methylenedioxymethamphetamine (MDMA, "ecstasy") and its stereoisomers as reinforcers in rhesus monkeys: serotonergic involvement. Psychopharmacology (Berl) (2002) 1.10
Structural analysis of thermostabilizing mutations of cocaine esterase. Protein Eng Des Sel (2010) 1.10
Central kappa-opioid receptor-mediated antidepressant-like effects of nor-Binaltorphimine: behavioral and BDNF mRNA expression studies. Eur J Pharmacol (2007) 1.09
Effects of intrathecally administered nociceptin/orphanin FQ in monkeys: behavioral and mass spectrometric studies. J Pharmacol Exp Ther (2006) 1.07
Roles of μ-opioid receptors and nociceptin/orphanin FQ peptide receptors in buprenorphine-induced physiological responses in primates. J Pharmacol Exp Ther (2012) 1.07
Hallucinogen-like actions of 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7) in mice and rats. Psychopharmacology (Berl) (2005) 1.07
BU74, a complex oripavine derivative with potent kappa opioid receptor agonism and delayed opioid antagonism. Eur J Pharmacol (2005) 1.07
Prevention and reversal by cocaine esterase of cocaine-induced cardiovascular effects in rats. Drug Alcohol Depend (2009) 1.07
Effects of selective dopaminergic compounds on a delay-discounting task. Behav Pharmacol (2011) 1.06
Long-lasting effects of a PEGylated mutant cocaine esterase (CocE) on the reinforcing and discriminative stimulus effects of cocaine in rats. Neuropsychopharmacology (2011) 1.06
The delta-opioid receptor agonist (+)BW373U86 regulates BDNF mRNA expression in rats. Neuropsychopharmacology (2004) 1.05
Activation of kappa-opioid receptors inhibits pruritus evoked by subcutaneous or intrathecal administration of morphine in monkeys. J Pharmacol Exp Ther (2003) 1.05
Long-lasting antinociceptive spinal effects in primates of the novel nociceptin/orphanin FQ receptor agonist UFP-112. Pain (2009) 1.05
Nantenine: an antagonist of the behavioral and physiological effects of MDMA in mice. Psychopharmacology (Berl) (2004) 1.05
Individual differences in discount rate are associated with demand for self-administered cocaine, but not sucrose. Addict Biol (2011) 1.04
The effects of CRF antagonists, antalarmin, CP154,526, LWH234, and R121919, in the forced swim test and on swim-induced increases in adrenocorticotropin in rats. Psychopharmacology (Berl) (2005) 1.04
Endogenous opioids upregulate brain-derived neurotrophic factor mRNA through delta- and micro-opioid receptors independent of antidepressant-like effects. Eur J Neurosci (2006) 1.04
Self-administration of fentanyl, cocaine and ketamine: effects on the pituitary-adrenal axis in rhesus monkeys. Psychopharmacology (Berl) (2004) 1.02
Separation of the convulsions and antidepressant-like effects produced by the delta-opioid agonist SNC80 in rats. Psychopharmacology (Berl) (2005) 1.02
Influence of conditioned reinforcement on the response-maintaining effects of quinpirole in rats. Behav Pharmacol (2009) 1.01
Morphine deprivation increases self-administration of the fast- and short-acting mu-opioid receptor agonist remifentanil in the rat. J Pharmacol Exp Ther (2008) 1.01
The role of central gastrin-releasing peptide and neuromedin B receptors in the modulation of scratching behavior in rats. J Pharmacol Exp Ther (2011) 1.00
A behavioral economic analysis of cocaine and remifentanil self-administration in rhesus monkeys. Psychopharmacology (Berl) (2007) 1.00
Behavioral effects of delta-opioid receptor agonists: potential antidepressants? Jpn J Pharmacol (2002) 0.99
Amelioration of the cardiovascular effects of cocaine in rhesus monkeys by a long-acting mutant form of cocaine esterase. Neuropsychopharmacology (2011) 0.98
Effects of cocaine esterase following its repeated administration with cocaine in mice. Drug Alcohol Depend (2009) 0.97
Peptidic delta opioid receptor agonists produce antidepressant-like effects in the forced swim test and regulate BDNF mRNA expression in rats. Brain Res (2005) 0.97
Corticotropin-releasing hormone antagonists, astressin B and antalarmin: differing profiles of activity in rhesus monkeys. Neuropsychopharmacology (2004) 0.96
Proerectile effects of dopamine D2-like agonists are mediated by the D3 receptor in rats and mice. J Pharmacol Exp Ther (2009) 0.96
Differential behavioral tolerance to the delta-opioid agonist SNC80 ([(+)-4-[(alphaR)-alpha-[(2S,5R)-2,5-dimethyl-4-(2-propenyl)-1-piperazinyl]-(3-methoxyphenyl)methyl]-N,N-diethylbenzamide) in Sprague-Dawley rats. J Pharmacol Exp Ther (2005) 0.95
The therapeutic potential of nociceptin/orphanin FQ receptor agonists as analgesics without abuse liability. ACS Chem Neurosci (2012) 0.94
Effects of pramipexole on the reinforcing effectiveness of stimuli that were previously paired with cocaine reinforcement in rats. Psychopharmacology (Berl) (2011) 0.94
The convulsive and electroencephalographic changes produced by nonpeptidic delta-opioid agonists in rats: comparison with pentylenetetrazol. J Pharmacol Exp Ther (2006) 0.93
An mHealth model to increase clinic attendance for breast symptoms in rural Bangladesh: can bridging the digital divide help close the cancer divide? Oncologist (2014) 0.93
Yawning and locomotor behavior induced by dopamine receptor agonists in mice and rats. Behav Pharmacol (2010) 0.92
Differential in vivo potencies of naltrexone and 6beta-naltrexol in the monkey. J Pharmacol Exp Ther (2005) 0.92
Characterization of butyrylcholinesterase antagonism of cocaine-induced hyperactivity. Drug Metab Dispos (2002) 0.91
Symptomatic phrenic nerve palsy after supraclavicular block in an obese man. Orthopedics (2009) 0.91
The treatment of chronic insomnia: drug indications, chronic use and abuse liability. Summary of a 2001 New Clinical Drug Evaluation Unit meeting symposium. Sleep Med Rev (2004) 0.89
Corticotropin-releasing factor receptor-1: a therapeutic target for cardiac autonomic disturbances. Expert Opin Ther Targets (2007) 0.89
Serotonin synthesis inhibition reveals distinct mechanisms of action for MDMA and its enantiomers in the mouse. Psychopharmacology (Berl) (2005) 0.89
Effects of mu, kappa, and delta opioid receptor agonists on the function of hypothalamic-pituitary-adrenal axis in monkeys. Psychoneuroendocrinology (2008) 0.89
The effects of nociceptin/orphanin FQ receptor agonist Ro 64-6198 and diazepam on antinociception and remifentanil self-administration in rhesus monkeys. Psychopharmacology (Berl) (2010) 0.89
Subunit stabilization and polyethylene glycolation of cocaine esterase improves in vivo residence time. Mol Pharmacol (2011) 0.89
The discriminative stimulus effects of dopamine D2- and D3-preferring agonists in rats. Psychopharmacology (Berl) (2008) 0.88
PEGylation of bacterial cocaine esterase for protection against protease digestion and immunogenicity. J Control Release (2009) 0.88
Physiological function of gastrin-releasing peptide and neuromedin B receptors in regulating itch scratching behavior in the spinal cord of mice. PLoS One (2013) 0.88
A choice procedure to assess the aversive effects of drugs in rodents. J Exp Anal Behav (2010) 0.88
Differential effects of opioid-related ligands and NSAIDs in nonhuman primate models of acute and inflammatory pain. Psychopharmacology (Berl) (2013) 0.87
Effects of a long-acting mutant bacterial cocaine esterase on acute cocaine toxicity in rats. Drug Alcohol Depend (2011) 0.87
Cardiovascular effects of nicotine, chlorisondamine, and mecamylamine in the pigeon. J Pharmacol Exp Ther (2003) 0.87
Effects of spinally administered bifunctional nociceptin/orphanin FQ peptide receptor/μ-opioid receptor ligands in mouse models of neuropathic and inflammatory pain. J Pharmacol Exp Ther (2013) 0.86
Behavioral and neurobiological effects of the enkephalinase inhibitor RB101 relative to its antidepressant effects. Eur J Pharmacol (2006) 0.86
Behavioral perspectives on the neuroscience of drug addiction. J Exp Anal Behav (2005) 0.85